Turkey Tail Mushrooms Help Immune System Fight Cancer

By Paul Stamets - Founder, Fungi Perfecti; Advisor, Program of Integrative Medicine at the University of Arizona Medical School, Tucson
A promising clinical study shows that the turkey tail mushroom (Trametes versicolor) improves the immune systems of breast cancer patients. The multiyear study, funded by the National Institutes of Health (NIH), tracked whether or not turkey tails could positively affect the immune system of patients rebound after they ended their radiation therapy.
Immunity -- as measured by the number of lymphocyte cells and natural killer cell activity -- usually declines dramatically after radiotherapy. Natural killer (NK) cells protect us from tumors and viruses. Researchers at the University of Minnesota Medical School and Bastyr University Research Institute hypothesized that breast cancer patients' health can be improved after radiation treatment if NK cell counts increased quickly to attack remaining cancerous cells.
The study titled "Phase I Clinical Trial of Trametes versicolor in Women with Breast Cancer," recently published month in the ISRN Oncology Journal, shows that turkey tail mushrooms can augment conventional therapies for treating breast cancer by increasing NK cell activity. This study suggests that turkey tail mushrooms are an effective adjunct to conventional chemotherapeutic medicines and radiation therapy. The authors concluded "research by our center continues to indicate that Trametes versicolorrepresents a novel immune therapy with significant applications in cancer treatment."
Due to its long history of therapeutic use, however, turkey tail prepared and packaged as an immune therapy drug is unlikely to be patentable, deterring big pharmas from conducting costly clinical studies. Typically, the longer the historical use of natural medicines for treating an ailment, the less likely derivatized drugs from these natural products will be patentable. To fill this research gap, the NIH established The National Center for Complementary and Alternative Medicine (www.nccam.nih.gov), which funded and oversaw this study. NIH's interest is not surprising -- more than 70 percent of new drugs are estimated to originate from natural sources.
Reader Comments